The Buzz Surrounding: Codebase Ventures Inc. (OTCQB: BKLLF) (CSE: CODE) | Financial Buzz

The Buzz Surrounding: Codebase Ventures Inc. (OTCQB: BKLLF) (CSE: CODE)

Codebase Ventures Inc. explains that it is comprised of a hands-on team of financial and technology experts who invest early in great ideas. The Company seeks out and empowers the innovators who are building tomorrow’s standards with platforms and protocols, not just products. Codebase Ventures invests early, supports founders, takes their ideas to market and works to help them realize their vision.

Codebase Ventures looks for early-stage opportunities focusing on talent, teams and technology:

  • Talent: Dedicated innovators with deep category expertise
  • Teams: Results-driven, hands-on management
  • Technology: Bold, real-world implementations of scalable tech

Our Behind the Buzz Show Featuring
Codebase Ventures Inc.

Investor Recap

Recent Breaking News: Drug Delivery System
for Hydroxychloroquine

“transforming delivery for a drug which may be a possible treatment for Covid-19 patients in the near term and a recognized treatment for malaria, lupus and rheumatoid arthritis patients in the long term”
The company emphasizes several factors regarding Hydroxychloroquine:
  • Hydroxychloroquine has been heavily publicized as a promising drug treatment available today for Covid-19
  • CODE has secured the rights to the recently applied patent application for a transdermal delivery system for hydroxychloroquine (HCQ)
  • The FDA has approved the use of HCQ for Covid-19 patients and health care workers in an unprecedented move
  • Formal studies are underway in the US, Canada, Europe, Asia, Australia, Africa and beyond and, while no formal clinical trial has yet proven its efficacy in relation to COVID 19, HCQ has been endorsed and prescribed widely by some physicians
  • With its partners, including an FDA approved lab in the US, CODE’s transdermal HCQ solution is primed to get to market as soon as legally possible, and it is clear the US Administration and the FDA are keen to advance solutions that make this drug more effective and more widely available in the immediate future
  • This transformative delivery system will be targeted in the short term on Covid-19, and in the long term for the drug’s FDA approved applications for malaria, lupus and rheumatoid arthritis – providing an innovation for those long-term patients who have depended on HCQ for decades and had to accept the side effects related to oral delivery.

ARCOLOGY

A cluster-computing powered AI blockchain ecosystem
with unlimited scalability

Scalable

Arcology’s scalability is magnitudes greater than other blockchains currently on the market – a single node cluster can scale without limits.

Compatible

With heterogeneous smart contracts running on the same platform, we offer cross-platform functionality without sidechains.

Flexible

Arcology’s architecture is suitable for both permissioned and permissionless scenarios, with many unique features.

Affordable

Thanks to very low transaction and storage fees, Arcology is the most developer-friendly decentralized network.

PRESSLAND

The first comprehensive map of the global media supply chain, built to restore public trust

Reclaiming public trust in media
through radical transparency.

Pressland is the first comprehensive map of the global media supply chain, built to restore public trust.

Recent Dvelopments

April 23rd, 2020 - Codebase Investment Adds Oral Mucosal Patent Filing, Expanding Transdermal Treatments

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF), an investment company, is excited to expand on its announcement on April 16th, 2020, as it relates to a new delivery mechanism for decades old drug used to treat malaria, lupus and rheumatoid arthritis.

Adding to the previously announced provisional patent filing for a transdermal patch delivery of hydroxychloroquine, the private company with which Codebase has entered into an arms-length agreement to acquire a 49% interest, Glanis Pharmaceuticals Inc, has filed for an additional US provisional patent for the novel oral drug delivery of hydroxychloroquine (HCQ) and chloroquine (CQ).

“With the previously announced transdermal patch filing, and now this novel oral delivery filing, steps are advancing quickly to satisfy a need for an improved drug delivery system of CQ and HCQ, which can replace the multiple dosage regimen associated with oral tablets and also decrease the probabilities of getting side effects related to GI tract disturbance,” said Codebase President and CEO, Mr. George Tsafalas.

  • CODE has agreed to acquire a 49% interest in a private company that has secured the rights to the recently applied provisional patent application for a novel oral drug delivery system for hydroxychloroquine (HCQ), in addition to the previously announced transdermal patch provisional patent filing.
  • This transformative delivery system will initially seek approval through the FDA 505(b)(2) accelerated pathway provisions.
  • These new drug delivery systems could potentially provide an innovation for those long-term patients suffering from malaria, lupus and rheumatoid arthritis who have depended on HCQ for decades and have had to accept the side effects related to oral tablet delivery.
  • While there has been widespread publicity concerning HCQ as a treatment for Covid-19, there has been no recognized drug trial results to date.

In oral mucosal drug delivery, an oral mucosal patch or orally disintegrating composition is applied to the mucosal surface of the oral cavity. Throughout the duration of the application of an oral mucosal patch or oral disintegrating composition, the drug is continuously released and delivered through the intact mucosa to achieve systemic effect. Therefore, once applied, oral disintegrating composition or oral mucosal method can deliver drug into systemic circulation throughout the day. Currently, RRL has started evaluating the possibility of delivering HCQ for more than one day using their novel oral drug delivery system.

Oral mucosal delivery can reduce the dosing frequency of chloroquine (CQ) and hydroxychloroquine (HCQ) which is currently administered orally 2-3 times a day. Moreover, in oral mucosal drug delivery, the drug is delivered slowly and continuously throughout the duration of oral application hence there are no peaks and troughs in drug plasma concentration which are associated with multiple dose administration in a day. With respect to CQ and HCQ, it is expected that adverse effects in patients will be less with the oral mucosal delivery as drug plasma concentration with oral mucosal delivery is less than peak plasma concentration associated with oral tablets.

As consideration for this additional provisional patent and on-going work, the Company will issue up to 6 million common shares and pay $20,000 USD pursuant to a lab services agreement with a New York based laboratory, Reformulation Research Laboratories Inc. (RRL), that developed the patent application and the underlying technology. These shares will be issued at a deemed price of $0.05 per share. The agreement is subject to closing conditions usually found in transactions of this kind.

While hydroxychloroquine is the subject of various early studies of its effectiveness against the Covid-19, its present on-label uses as a treatment against malaria, lupus and rheumatoid arthritis provides a ready market for this proposed new delivery system. This new delivery method can eliminate or reduce a number of the common side effects of this treatment, including nausea, vomiting, loss of appetite, diarrhea, dizziness, or headache by providing a controlled constant delivery.

RRL has a combined 75 years of expertise in novel drug delivery systems that provide the capacity, equipment and capabilities to advance the development program for a hydroxychloroquine molecule for oral mucosal delivery from research, testing, regulatory approvals through to launch of the hydroxychloroquine oral mucosal delivery system.

The Company’s scientific expert has read and approved the scientific disclosures contained in the press release. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 at this time. RRL is not making any express or implied claims that any of its products have the ability to deliver hydroxychloroquine through transdermal/oral at this time.

For Full Release – https://www.accesswire.com/586422/Codebase-Investment-Adds-Oral-Mucosal-Patent-Filing-Expanding-Transdermal-Treatments

April 21st, 2020 - Hydroxychloroquine Side Effects Potentially Mitigated by Transdermal Delivery

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF), an investment company, is pleased to expand upon its announcement of April 16th regarding its agreement to acquire a 49% interest in an arms-length private company with the rights to a provisional patent for a transdermal drug delivery system for hydroxychloroquine (HCQ) to treat malaria, lupus and rheumatoid arthritis.

Hydroxychloroquine has been heavily publicized in relation to its potential treatment and prevention role with Covid-19, leading to instances of self medication, where “hydroxychloroquine can have dangerous side-effects if the dose is not carefully controlled.”1,2

  • In oral tablet form, hydroxychloroquine side effects include headache, dizziness, diarrhea, vomiting, blurred vision, and arrhythmia among others3
  • Transdermal delivery of hydroxychloroquine regulates dosage, improving patient compliance and outcomes4
  • Bypassing the GI tract mitigates gastrointestinal side effects
  • Transdermal delivery is more efficient, therefore requiring less of the active ingredient to be administered

The hydroxychloroquine transdermal drug delivery system to be developed by an investee company of Codebase is designed to control dosage and to deliver the prescribed amount of the drug over the prescribed time period without inconsistencies inherent in oral tablet delivery – the premise being that transdermal delivery can reduce and/or eliminate side effects associated with uncontrolled dosing.

Reformulation Research Laboratories Inc. (RRL), Code’s contract lab partners in the venture, have provided that transdermal delivery of hydroxychloroquine can result in improved well being for patients by providing constant drug levels, fewer side effects overall, highlighted by the fact unlike oral tablets, transdermal delivery bypasses the gastrointestinal tract which can eliminate side effects from that route such as nausea. In addition, limitations on bioavailability and metabolism of the active ingredient when taken orally require dosages to be higher than what is required for therapeutic results. Transdermal delivery is more efficient, and with greater bioavailability and therefore lower amounts of the active ingredient are required, which also can improve outcomes for patients.

The Company’s scientific expert has read and approved the scientific disclosures contained in the press release. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 at this time. RRL is not making any express or implied claims that any of its products have the ability to deliver hydroxychloroquine through transdermal at this time.

1 https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30089-8/fulltext

2 https://nationalpost.com/news/politics/canada-quietly-secured-order-for-5-millions-pills-of-anti-malaria-medication-eyed-as-potential-covid-19-treatment

https://www.healthline.com/health/hydroxychloroquine-oral-tablet

4 https://www.sciencedirect.com/topics/medicine-and-dentistry/transdermal-drug-administration

For Full Release – https://www.accesswire.com/585986/Hydroxychloroquine-Side-Effects-Potentially-Mitigated-by-Transdermal-Delivery

April 20th, 2020 - Hydroxychloroquine Treatment for COVID-19 Benefits Sought in Global Research Effort to Establish Efficacy

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF), an investment company, is pleased to build upon its announcement of April 16th regarding its binding letter of intent to invest in an arms-length private company with rights to a provisional patent for a transdermal drug delivery system for hydroxychloroquine (HCQ), a drug currently used to treat malaria, lupus and rheumatoid arthritis, and being tested as a potential treatment for COVID-19. Hydroxychloroquine is now being tested on a global basis for the treatment and prevention of COVID-19, highlights include:

  • World Health Organization launches Solidarity clinical trial now in 90 countries on treatment efficacy
  • UK wide randomized, controlled trial in over 130 hospitals called Recovery is underway
  • NYU and University of Washington fast track major clinical trial to determine role of HCQ in prevention of coronavirus

Approved by the FDA for malaria, lupus and rheumatoid arthritis, hydroxychloroquine and chloroquine are one of four potential treatments that the World Health Organization has included in its global Solidarity Clinical Trial for COVID-19 Treatments.Currently, there are 90 countries participating in Solidarity.

As it relates to hydroxychloroquine and chloroquine, clinical trials focus upon the drug’s application for autoimmune diseases like lupus and rheumatoid arthritis, where the drug works to lessen the impacts of an overactive immune system, and HCQ’s potential antiviral effects, which have been demonstrated in test-tube scenarios. The potential benefit to COVID-19 patients include the potential to mitigate an overactive immune system response where the body is essentially attacking itself and on the antiviral front, the hypothesis is that it could prevent the virus from attacking cells and replicating.2,3

The world’s largest randomized, controlled clinical trial of potential coronavirus treatments has begun in the UK, where hydroxychloroquine is one of four treatments being studied across 130 hospitals.4 Named Recovery, the trial is funded by a grant to the University of Oxford from the U.K. Research and Innovation/National Institute for Health Research (NIHR) and the Bill and Melinda Gates Foundation, among other organizations.5

In the United States, a major randomized controlled clinical trial focused on the preventative role hydroxychloroquine can play in relation to COVID-19 has been fast tracked and now has its first patients – the study is jointly led by NYU Langone and the University of Washington.6

“It is encouraging to see the momentum on these studies build so rapidly to address the current pandemic,” said Mr. George Tsafalas, Code President and CEO. “The influx of new information and precedent supports our lab partners in the process of conducting their initial phase of literature search and reformulation studies as previously announced.”

The Company is not making any express or implied claims that hydroxychloroquine or chloroquine has the ability to eliminate, cure or contain COVID-19 at this time.

https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-COVID-19-treatments

2 https://www.macleans.ca/society/science/these-drugs-are-being-tested-on-COVID-19-do-any-of-them-work/

3 https://www.livescience.com/chloroquine-coronavirus-treatment.html

4 https://www.ctvnews.ca/health/coronavirus/world-s-largest-randomized-trial-on-COVID-19-treatments-launched-1.4900612

5 https://www.recoverytrial.net/

6 https://www.cnbc.com/2020/04/15/coronavirus-us-clinical-trials-of-hydroxychloroquine-hit-warp-speed.html

For Full Release – https://www.accesswire.com/585850/Hydroxychloroquine-Treatment-for-COVID-19-Benefits-Sought-in-Global-Research-Effort-to-Establish-Efficacy

April 16th, 2020 - Codebase to invest in company developing hydroxychloroquine transdermal treatment

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE: CODE – FSE: C5B – OTCQB: BKLLF), an investment company, is excited to announce that it has finalized an agreement, securing the rights to an innovative drug delivery system for hydroxychloroquine – transforming the delivery of the drug which may be a possible treatment for Covid-19 patients in the near term and a recognized treatment for malaria, lupus and rheumatoid arthritis patients over the long term.

“Codebase has finalized an exclusive agreement to launch an innovative transdermal patch for hydroxychloroquine,” said Mr. George Tsafalas, Codebase President & CEO. “Hydroxychloroquine in its current decades-old oral tablet form is subject to inconsistent dosing and side effects including nausea, vomiting, blurred vision, headache and overall toxicity. A transdermal patch should possibly remedy side effects by delivering the drug consistently in the right dose and bypassing the GI tract where the side effects originate.”

  • Hydroxychloroquine has been heavily publicized as a promising drug treatment available today for Covid-19
  • CODE has secured the rights to the recently applied patent application for a transdermal delivery system for hydroxychloroquine (HCQ)
  • The FDA has approved the use of HCQ for Covid-19 patients and health care workers in an unprecedented move
  • Formal studies are underway in the US, Canada, Europe, Asia, Australia, Africa and beyond and, while no formal clinical trial has yet proven its efficacy in relation to COVID 19, HCQ has been endorsed and prescribed widely by some physicians
  • With its partners, including an FDA approved lab in the US, CODE’s transdermal HCQ solution is primed to get to market as soon as legally possible, and it is clear the US Administration and the FDA are keen to advance solutions that make this drug more effective and more widely available in the immediate future
  • This transformative delivery system will be targeted in the short term on Covid-19, and in the long term for the drug’s FDA approved applications for malaria, lupus and rheumatoid arthritis – providing an innovation for those long-term patients who have depended on HCQ for decades and had to accept the side effects related to oral delivery.

Codebase has entered into an arms-length agreement to acquire a 49% interest in a private company that has recently filed for a US patent for the transdermal delivery of hydroxychloroquine. The Company will issue up to 35 million common shares to the shareholders of this private company, as well as another 25 million shares pursuant to a lab services agreement with a New York based laboratory that developed the patent application and the underlying technology. These shares will be issued at a deemed price of $0.05 per share. The agreement is subject to closing conditions usually found in transactions of this kind.

While hydroxychloroquine is the subject of various early studies of its effectiveness against the Covid-19, its present on-label uses as a treatment against malaria, lupus and rheumatoid arthritis provides an already sizable market for this proposed new delivery system. This new development should eliminate a number of the common side effects of this treatment, including nausea, vomiting, loss of appetite, diarrhea, dizziness, or headache by providing a controlled constant dose.

Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time, drastically reducing side effects from decades-old oral tablets. Safe, consistent doses will make the drug much more effective.

For Full Release – https://www.accesswire.com/585319/Codebase-to-Invest-in-Company-Developing-Hydroxychloroquine-Transdermal-Treatment

April 3, 2020 - Codebase Provides Update on Its Holdings and Near-Term Investment Priorities

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF), an investment company, provides updates on progress with its holdings World High Life PLC and Arcology, the current status of Pressland and the Company’s future looking investment focus.

World High Life PLC is an investment company with a strategic focus to invest in or acquire companies operating in the CBD wellness and medicinal cannabis industry. It’s fully owned subsidiary, Love Hemp, is a leading CBD supplier in the UK. Love Hemp has deployed the capital investments made in the company to expand its product line and broaden its sales and distribution, resulting in record monthly sales through the combination of its retail presence and its ecommerce site.

Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, is advancing its presence amongst dAPP developers by launching a project on GitHub.com, the world’s largest source code sharing platform. “With this intelligent client-end simulator, which we call Ammolite, the goal is to demonstrate Arcology’s scalability, ease of use and compatibility within the developer community – a community that will be crucial in the adoption and use of Arcology into the future,” said Arcology Founder and Chief Scientist Laurent Zhang.

The Ammolite simulator works closely with ParallelKitties – which is a supercharged version of CryptoKitties – deployed on the Arcology network, demonstrating the ease of developing super high-performance applications on Arcology. Ammolite simulates hundreds of thousands of dAPPs users on the network simultaneously.

In the current business climate, the Company’s Pressland investment is being put on hold to deploy resources in the most effective manner where shareholder returns in the near term are prioritized. Leadership and the Board of Directors will re-evaluate prospects for the business model as the current health and economic crisis unfolds over the coming months.

Leveraging its extensive network in the medical science sector, the Company’ leadership, board and advisors are actively pursuing pharmaceutical investment opportunities that can have a positive impact on the current global health care crisis as a result of COVID -19.

For Full Release – https://www.accesswire.com/583723/Codebase-Provides-Update-on-Its-Holdings-and-Near-Term-Investment-Priorities

February 20, 2020 - Code Finalizes Strategic Investment in Mobile Game App Trad3r

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF), an investment company, announces that it has finalized an arms-length equity investment in Trad3r, a UK-based virtual immersive social platform app that allows users to trade a wide range of options – from celebrities and sports teams to Instagram stories and stocks – with real money, in exchange for rewards at the world’s best companies.

Codebase has invested CAD $105,000 in Trad3r parent company, Aerosax Research and Technology Ltd., of the UK. Codebase is excited to support the expansion plans for Trad3r, building upon its proven model, growing it’s following, participation and reach into new markets internationally.

The app, first launched in 2017, has already reached 4.3 million users and has a target of 10 million by 2021. The company is readying for a UK tour in March, hitting cities including Edinburgh, Manchester, Leicester and Bristol prior to launching its international expansion strategy into over 30 countries.

Trad3r Highlights – Celebrities, Sports, Stocks, Friends

  • 4.3 M total active users
  • 440,000 highest daily active users
  • 103,000 daily purchases
  • 1 billion monthly interactions

“The Trad3r app has a proven track record, attracting users and investment in the UK,” said Codebase President and CEO, Mr. George Tsafalas. “This is a rapid growth sector and the unique proposition, combining stocks with celebrities, fantasy sports and one’s own social network is working to show that Millennials and Gen Z’s are seeking new methods of engagement, and we believe our shareholders will benefit greatly through this early stage investment in an innovator like Trad3r.”

For Full Release: https://www.accesswire.com/577078/Code-Finalizes-Strategic-Investment-in-Mobile-Game-App-Trad3r

February 19, 2020 - Arcology Launches Testing of Ethereum Applications

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF), an investment company, is pleased to announce that the Arcology technical team is launching its comprehensive testing of the high profile Ethereum game called CryptoKitties on its own internal testnet.

CryptoKitties is a very well-known game that runs on the Ethereum network, and which has caused serious network congestions because of its transaction volume. Using this example to illustrate Arcology’s speed and scalability provides a purposeful comparison and validation of the platform’s capabilities.

Multiple blockchain technology projects have endeavoured to solve the scalability issue with different approaches with no demonstrated, major success to date. Arcology has a very unique solution to address that problem, featuring the following capabilities:

  • Arcology allows multiple transactions to be processed in parallel
  • Transaction processing can scale up linearly based upon number of computers available
  • Fully compatible with Ethereum platform
  • Popular Ethereum applications like CryptoKitties can work on Arcology smoothly
  • Ethereum developers can start to work on Arcology right away
  • Minimized migration costs

The purpose of this test is to demonstrate Arcology’s technical advantages, scalability and transaction per second speed.

“CryptoKitties was the major event within the whole blockchain industry when the overall challenge of scalability became evident. This Arcology test serves as a showcase, with the goal of demonstrating Arcology’s technical superiority. It is an internal test, a prelude for our public benchmarking and demonstration in the near future,” said Mr. Laurent Zhang, President of Arcology.

Trad3r Highlights – Celebrities, Sports, Stocks, Friends

  • 4.3 M total active users
  • 440,000 highest daily active users
  • 103,000 daily purchases
  • 1 billion monthly interactions

“The Trad3r app has a proven track record, attracting users and investment in the UK,” said Codebase President and CEO, Mr. George Tsafalas. “This is a rapid growth sector and the unique proposition, combining stocks with celebrities, fantasy sports and one’s own social network is working to show that Millennials and Gen Z’s are seeking new methods of engagement, and we believe our shareholders will benefit greatly through this early stage investment in an innovator like Trad3r.”

For Full Release: https://www.accesswire.com/576916/Arcology-Launches-Testing-of-Ethereum-Applications

February 12, 2020 - From Coast to Coast, Regions are Decriminalizing Natural Psychedelics

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF), an investment company, on behalf of its subsidiary, Titan Shrooms and Psychedelics, is pleased to provide an overview of the rapidly changing environment for natural psychedelics in the USA.

There is a growing body of scientific research, as reported by 60 Minutes,1 indicating that psilocybin can be used to effectively treat mental illnesses such as anxiety, depression and PTSD – and more so where these conditions are entrenched and current drugs are not proving effective. A study reported in the journal Nature,2 showed that 47% of patients with treatment resistant depression who received psilocybin were showing positive outcomes 5 weeks post treatment.

In addition, the FDA has granted “breakthrough therapy” status to both the Usona Institute and Compass Pathways, allowing clinical trials to advance – a measure the organization deploys where evidence indicates there could be substantial improvement over currently available treatments.3

As a result of this movement, stigmas are being reduced and cities and regions are moving quickly to decriminalize natural psychedelics such as psilocybin including:

  • Santa Cruz, California
  • Denver, Colorado
  • Oakland, California

Pending measures underway in:

  • Chicago, Illinois
  • Oregon
  • Iowa
  • Vermont
  • Michigan
  • Washington, D.C.

“Although in early stages, this rapidly developing field is being validated by the medical establishment, legislative bodies and most importantly patients who are seeing benefits,” said Mr. George Tsafalas. “Titan Shrooms and Psychedelics is working to add to its portfolio so that Code shareholders can benefit from the continued acceptance and growth in this sector.”

https://www.cbsnews.com/news/psychedelic-drugs-lsd-active-agent-in-magic-mushrooms-to-treat-addiction-depression-anxiety-60-minutes-2019-12-29/

https://www.nature.com/articles/s41598-017-13282-7

3 https://pharmaphorum.com/news/fda-tags-psilocybin-drug-as-clinical-depression-breakthrough-therapy/

For Full Release: https://www.accesswire.com/576097/Code-Subsidiary-Titan-Shrooms-and-Psychedelics-Recognizes-Widening-Acceptance-of-Psilocybin-Throughout-the-USA

February 5, 2020 - Code Subsidiary - Titan Shrooms & Psychedelics - Signs LOI with Medicinal Mushroom Biotech Company Mycology Ventures to Form Joint Venture

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF), an investment company, is pleased to announce that its subsidiary, Titan Shrooms and Psychedelics has signed a letter of intent to form a joint venture with arms-length mushroom biotech company Mycology Ventures. The resulting joint venture would see Titan holding a 70% interest.

Mycology’s leadership brings extensive experience and combined networks from the cannabis, CBD and mushroom sectors, in addition to medical and academic research fields, which will be deployed to identify and secure early stage investment opportunities to benefit CODE shareholders.

The joint venture will be structured to include cash and shares, although no amounts of either have been determined yet. Investment will be tied to significant milestones including the following in the near term:

  • Identification and evaluation of 1-3 investment opportunities that align to Mycology’s investment principles
  • Continued industry networking through attendance at 2-5 qualified conferences
  • Continue buildout of Advisory Board through PhD network at multiple universities

Mycology Ventures is taking a science and medicine first approach to identifying and bringing to market revolutionary alternatives for those suffering from mental health and addiction illnesses. Mycology is founded on the principle that psychedelic medicine is experiencing a revival as a result of recent research studies and significant signals of support from regulators as reported on major media properties, including an in-depth report on 60 minutes.1

“The US, along with many other countries, is illustrative of the dangers of opioid and anti-depressant pharmacology,” said Mr. George Tsafalas, Code CEO. “The resulting openness to viable alternatives, including psilocybin, by regulatory bodies and major research institutions is a strong indicator of the potential for this sector. As it relates to psilocybin for depression, the FDA has granted a ‘breakthrough therapy’ designation to advance legal clinical trials, which indicates that we are at the start of pioneering effort to reshape medicine as it applies to mental illness, pain management and addiction.”

Indicators of Regulatory and Market Acceptance

“Mycology plans to incubate cutting edge approaches in the space, uniting academics and producers to monetize their ideas and techniques with the goal of helping bring this amazing alternative approach to market to benefit people suffering from mental health illnesses,” added Mr. Tsafalas.

1 https://www.cbsnews.com/news/psychedelic-drugs-lsd-active-agent-in-magic-mushrooms-to-treat-addiction-depression-anxiety-60-minutes-2019-12-29

 

For Full Release: https://www.accesswire.com/575252/Code-Subsidiary–Titan-Shrooms-Psychedelics–Signs-LOI-with-Medicinal-Mushroom-Biotech-Company-Mycology-Ventures-to-Form-Joint-Venture 

February 4, 2020 - Code Investment World High Life Announces Georges St-Pierre as Brand Ambassador Featuring Its Love Hemp Brand

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF), an investment company, is thrilled to announce that 3-time UFC Champion of the World, Georges St-Pierre (www.gspofficial.com), is now the featured brand ambassador for World High Life (NEX: LIFE)(www.worldhighlife.uk) and its Love Hemp brand (www.love-hemp.com).

As previously announced, Codebase Ventures has made an investment in World High Life.

Georges “Rush” St-Pierre, also known as “GSP,” is a Canadian professional mixed martial artist and UFC world champion who holds black belts in both Kyokushin karate and Brazilian Jiu Jitsu.

In 2006 he became the UFC Welterweight Champion. He lost the title in 2007 but subsequently regained it in front of his hometown fans of Montreal in 2008 and hasn’t lost a single title defense since then.

“Georges St-Pierre represents a world champion standard and following that will greatly benefit the growth of the Love Hemp CBD health and wellness brand and sales of its product portfolio,” said Code Director, Mr. Brian Keane. “As Love Hemp and World High Life expand throughout the UK, into Europe and beyond, GSP will add tremendous power to the mix and differentiate the offering throughout the world.”

“Using Love Hemp’s CBD products in my training helped my recovery and overall well being greatly, I embrace this opportunity to help create innovative products and grow the Love Hemp brand so that others can benefit as well,” said Mr. Georges St-Pierre. “I am committed to building great teams and getting world class results in everything I do, and the World High Life and Love Hemp team have shown me they have everything it takes to achieve that world class standard.”

As Brand Ambassador, Mr. St-Pierre will facilitate and provide promotional services, including branding, social media, product placement, endorsement and overall support of the Company and the “Love Hemp” brand.

Georges St-Pierre Highlights

  • Born in St-Isidore, Québec, on 19 May 1981
  • 26 wins (8 by knockout, 6 by submission, 12 by decision) 2 defeats
  • Two-time Welterweight Champion of the World, including nine consecutive successful title defenses from 2008 to 2013 – Ultimate Fighting Championship (UFC)
  • Middleweight Champion of the World, 2017 – Ultimate Fighting Championship (UFC)
  • Fighter of the Year 2009 – Sports Illustrated, World MMA Awards, MMAPayout, Inside MMA, MMAJunkie
  • Canadian Athlete of the Year 2008, 2009, 2010 – Rogers Sportsnet
  • Finalist – Best Fighter 2008, 2010, 2011, 2018 – ESPY Awards
  • Most Dangerous Man of the Year 2010 – Spike Guys Choice Awards
  • 2008 MMA Fighter of the Year – Black Belt Magazine

 

For Full Release: https://www.accesswire.com/575079/Code-Investment-World-High-Life-Announces-Georges-St-Pierre-as-Brand-Ambassador-Featuring-Its-Love-Hemp-Brand

  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For codebase ventures inc. financial and corporate news dissemination, FinancialBuzz.com has been compensated twenty thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.